Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, July 19th. Investors of record on Tuesday, August 13th will be paid a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.69%. The ex-dividend date is Monday, August 12th. View Allergan's Dividend History.

Allergan declared that its board has authorized a stock buyback program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.34 by $0.04. The business had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The company's revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.42 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 brokerages have issued twelve-month price targets for Allergan's stock. Their forecasts range from $144.95 to $255.00. On average, they anticipate Allergan's share price to reach $179.15 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News stories about AGN stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest in September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average trading volume of 3,600,000 shares, the short-interest ratio is currently 2.9 days. Currently, 3.2% of the company's stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.54%), Strs Ohio (0.20%), Rhumbline Advisers (0.15%), Calamos Advisors LLC (0.10%), Commerzbank Aktiengesellschaft FI (0.09%) and State of New Jersey Common Pension Fund D (0.08%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Envestnet Asset Management Inc., West Coast Financial LLC, Confluence Investment Management LLC, Meeder Asset Management Inc. and Farmers & Merchants Investments Inc.. View Insider Buying and Selling for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Strs Ohio, Alpine Group USVI LLC, Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $175.00.

Allergan has a market capitalization of $57.42 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]